Skip to content
10-K

Annual Report

FATE THERAPEUTICS, INC. FATE

0000950170-25-033510

← back to feed
Filed
Mar 5, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2024 · Feb 25, 2025 114.6M sh
Shares Diluted FY 2024 · Dec 31, 2023 98.41M sh
Capex FY 2024 · Dec 31, 2023 $6.15M
Operating Cash Flow FY 2024 · Dec 31, 2023 −$132.26M
Short Term Investments FY 2024 · Dec 31, 2023 $273.31M
Cash And Equivalents FY 2024 · Dec 31, 2023 $41.87M
Current Liabilities FY 2024 · Dec 31, 2023 $39.09M
Current Assets FY 2024 · Dec 31, 2023 $331.54M
Total Assets FY 2024 · Dec 31, 2023 $506.22M
Eps Diluted FY 2024 · Dec 31, 2023 −$1.64
Eps Basic FY 2024 · Dec 31, 2023 −$1.64
Sga Expense FY 2024 · Dec 31, 2023 $81.45M
Rd Expense FY 2024 · Dec 31, 2023 $172.6M
Net Income FY 2024 · Dec 31, 2023 −$160.93M
Operating Income FY 2024 · Dec 31, 2023 −$190.51M
Revenue FY 2024 · Dec 31, 2023 $63.53M
Stockholders Equity FY 2024 · Dec 31, 2022 $483.94M